Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
The European Journal of Health Economics
Erschienen in: The European Journal of Health Economics 4/2014

01.05.2014 | Editorial

Orphan drugs policies: a suitable case for treatment

verfasst von: Michael Drummond, Adrian Towse

Erschienen in: The European Journal of Health Economics | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Context

Current orphan drug policies are unsatisfactory when viewed from almost all perspectives. Patients find that, although therapies are available for many rare conditions, access to care is sometimes restricted. Pharmaceutical manufacturers have responded to the incentives for research embodied in orphan drug legislation, only to find that funds are not made available to pay for therapies once developed. Those funding health care find that most orphan drugs do not justify funding based on standard value for money criteria, yet that they face political problems if they fail to provide funding for therapy.

Methods

A literature review was conducted in order to determine the precise nature of the problems and to suggest potential solutions.

Results

Current orphan drug policies are not fit for the purpose and initiatives need to be taken in the areas of (1) clarifying society’s views about the priority to be given to orphan drugs, (2) revising the arrangements for pricing and reimbursement of orphan drugs, (3) defining the priorities for research into rare diseases and (4) developing ‘joined up’ policies to deal with these issues.

Conclusions

Without changes in the current policies, pharmaceutical companies will eventually cease responding to the incentives to develop orphan drugs, because they will increasingly be uncertain whether the drugs, if developed, will be reimbursed.
Literatur
1.
Franco, P.: Orphan drugs: the regulatory environment. Drug Discov. Today 18, 163–172 (2013)PubMedCrossRef
2.
Drummond, M.F., Schwartz, J.S., Jönsson, B., Luce, B.R., Neumann, P., Sullivan, S.D.: Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int. J. Technol. Assess. Health Care 24(3), 244–258 (2008)PubMed
3.
Drummond, M.F., Wilson, D.A., Kanavos, P., Ubel, P., Rovira, J.: Assessing the economic challenges posed by orphan drugs. Int. J. Technol. Assess. Health Care 23, 36–42 (2007)PubMed
4.
McCabe, C., Claxton, K., Tsuchiya, A.: Orphan drugs and the NHS: should we value rarity? Br. Med. J. 331, 1016–1019 (2005)CrossRef
5.
Côté, A., Keating, B.: What it wrong with orphan drug policies? Value Health 15, 1185–1191 (2012)PubMedCrossRef
6.
7.
Linley, W.G., Hughes, D.A.: Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross sectional survey of 4118 adults in Great Britain. Health Econ. 22, 948–964 (2013)PubMedCrossRef
8.
Desser, A.S., Gyrd-Hansen, D., Olsen, J.A., Grepperud, S., Kristiansen, I.S.: Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. Br. Med. J. 341, c4715 (2010)CrossRef
9.
Culyer, A.J.: Need: the idea won’t do—but we still need it. Soc. Sci. Med. 40(6), 727–730 (1995)PubMedCrossRef
10.
McCabe, C., Stafinski, T., Menon, D.: Is it time to revisit orphan drug policies? Br. Med. J. 341, c4777 (2010)CrossRef
11.
Bridges, J.F.P., Hauber, A.B., Marshall, D., Lloyd, A., Prosser, L., et al.: Conjoint analysis applications in health—a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health 14, 403–413 (2011)PubMedCrossRef
12.
Nord, E.: The trade-off between severity of illness and treatment effect in cost-value analysis of health care. Health Policy 24, 227–238 (1993)PubMedCrossRef
13.
Mestre-Ferrandiz, J., Sussex, J., Towse, A.: The R&D Cost of a New Medicine. Office of Health Economics, London (2012)
14.
Meekings, K.N., Williams, C.S.M., Arrowsmith, J.E.: Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov. Today 17, 660–664 (2012)PubMedCrossRef
15.
Drummond, M.F., Wilson, D.A., Kanavos, P., Ubel, P.A., Rovira, J.: Assessing the challenges posed by orphan drugs: a response to McCabe et al. Int. J. Technol. Assess. Health Care 23, 401–404 (2007)
16.
Department of Health (UK): A New Value-Based Approach to the Pricing of Branded Medicines: a Consultation. Department of Health, London (2011)
17.
Sussex, J., Rollet, P., Garau, M., Schmitt, C., Kent, A., Hutchings, A.: Multi-Criteria Decision Analysis to Value Orphan Medicines. OHE Research Paper 13/03. Office of Health Economics, London (2013)
18.
Phillips, L.D., Fasolo, B., Zafiropoulos, N., Beyer, A.: Is quantitative benefit-risk modelling of drugs desirable or possible? Drug Discov. Today: Technol. 8(1), e3–e10 (2011)CrossRef
19.
Towse, A., Danzon, P.: The regulation of the pharmaceutical industry. In: Baldwin, R., Cave, M., Lodge, M. (eds.) Oxford Handbook on Regulation, pp. 548–571. Oxford University Press, New York (2010)
20.
Kanavos, P., Nicod, E.: What is wrong with orphan drug policies? Suggestions for ways forward. Value Health 15, 1182–1184 (2012)PubMedCrossRef
21.
Winquist, E., Bell, C.M., Clarke, J.T.R., Evans, G., Martin, J., et al.: An evaluation framework for funding drugs for rare diseases. Value Health 15, 982–986 (2012)PubMedCrossRef
22.
Daniels, N., Sabin, J.: Setting Limits Fairly: can we Learn to Share Medical Resources. Oxford University Press, Oxford UK (2002)CrossRef
23.
Clarke, J.T.R.: Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. Can. Med. Assoc. J. 174, 189–190 (2006)CrossRef
24.
Garau, M., Mestre-Ferrandiz, J.: Access Mechanisms for Orphan Drugs: a Comparative Study of Selected European Countries.OHE Briefing No. 52. Office of Health Economics, London (2009)
25.
26.
27.
Laupacis, A.: Economic evaluations in the Canadian Common drug review. Pharmacoeconomics 24(11), 1157–1162 (2006)PubMedCrossRef
28.
Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A.-P., et al.: Challenges in the development and reimbursement of personalized medicine: payer and manufacturer perspective and implications for health economics and outcomes research. Report of the ISPOR Personalized Medicine Special Interest Group. Value Health 15, 1162–1171 (2012)PubMedCrossRef
29.
Banerjee, A., Hollis, A., Pogge, T.: The health impact fund: incentives for improving access to medicines. Lancet 375(9709), 166–169 (2010)PubMedCrossRef
30.
Towse A, Keuffel E, Kettler HE, Ridley DB.: Drugs and vaccines for developing countries. In Danzon, P. and. Nicholson, S (eds). The Oxford Handbook of the Economics of the Biopharmaceutical Industry. OUP. (2012)
31.
Matlin, S.A., et al. (eds.): Health partnerships review: focusing collaborative efforts on research and innovation for the health of the poor. Glob. Forum Health Res., Geneva (2008)
32.
33.
Berndt, E.R., et al.: Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. Health Econ. 16(5), 491–511 (2007)PubMedCrossRef
34.
Orphanet. 2012. Prevalence of rare diseases: bibliographic data. Orphanet report series: rare diseases collection. www.​orpha.​net
35.
Minister for health, youth and sports (France).: National strategies and action for rare diseases in Europe. Paris (2008)
36.
Institute of Medicine: Rare Diseases and Orphan Products: Accelerating Research and Development. Institute of Medicine, Washington (2010)
Metadaten
Titel
Orphan drugs policies: a suitable case for treatment
verfasst von
Michael Drummond
Adrian Towse
Publikationsdatum
01.05.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
The European Journal of Health Economics / Ausgabe 4/2014
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-014-0560-1

Weitere Artikel der Ausgabe 4/2014

The European Journal of Health Economics 4/2014 Zur Ausgabe

Original Paper

Announcement effects of health policy reforms: evidence from the abolition of Austria’s baby bonus

Original Paper

Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain

Original Paper

Optimal choice on prevention and cure: a new economic analysis

Erratum

Erratum to: Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD

Original Paper

Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD

Original Paper

Explaining differences in remuneration rates of nursing homes in Germany